Moderna, Inc. (MRNA) DCF Valuation
- ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
- ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
- ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
- ✓ Aucune Expertise N'Est Requise; Facile À Suivre
Moderna, Inc. (MRNA) Bundle
Optimize your Moderna, Inc. (MRNA) valuation analysis using our cutting-edge DCF Calculator! This Excel template comes preloaded with actual MRNA data, enabling you to adjust forecasts and assumptions to accurately determine the intrinsic value of Moderna, Inc. (MRNA).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 48.0 | 274.5 | 17,736.0 | 19,263.0 | 6,848.0 | 9,316.0 | 12,673.5 | 17,241.0 | 23,454.7 | 31,907.7 |
| Revenue Growth, % | 0 | 471.43 | 6361.44 | 8.61 | -64.45 | 36.04 | 36.04 | 36.04 | 36.04 | 36.04 |
| EBITDA | -515.0 | -732.0 | 13,528.0 | 9,768.0 | -3,283.0 | -2,253.7 | -3,065.9 | -4,170.9 | -5,674.1 | -7,719.0 |
| EBITDA, % | -1072.11 | -266.68 | 76.27 | 50.71 | -47.94 | -24.19 | -24.19 | -24.19 | -24.19 | -24.19 |
| Depreciation | 31.0 | 31.3 | 232.0 | 348.0 | 621.0 | 1,642.4 | 2,234.3 | 3,039.5 | 4,134.9 | 5,625.1 |
| Depreciation, % | 64.58 | 11.39 | 1.31 | 1.81 | 9.07 | 17.63 | 17.63 | 17.63 | 17.63 | 17.63 |
| EBIT | -546.0 | -763.3 | 13,296.0 | 9,420.0 | -3,904.0 | -2,480.7 | -3,374.7 | -4,591.0 | -6,245.6 | -8,496.5 |
| EBIT, % | -1136.69 | -278.06 | 74.97 | 48.9 | -57.01 | -26.63 | -26.63 | -26.63 | -26.63 | -26.63 |
| Total Cash | 1,103.0 | 4,608.0 | 10,727.0 | 9,902.0 | 8,604.0 | 7,674.3 | 10,440.1 | 14,202.7 | 19,321.3 | 26,284.6 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 5.4 | 1,408.0 | 3,175.0 | 1,385.0 | 892.0 | 2,781.7 | 3,784.2 | 5,148.0 | 7,003.3 | 9,527.3 |
| Account Receivables, % | 11.18 | 512.95 | 17.9 | 7.19 | 13.03 | 29.86 | 29.86 | 29.86 | 29.86 | 29.86 |
| Inventories | .0 | 47.0 | 1,441.0 | 949.0 | 202.0 | 617.2 | 839.6 | 1,142.2 | 1,553.8 | 2,113.8 |
| Inventories, % | 0 | 17.12 | 8.12 | 4.93 | 2.95 | 6.62 | 6.62 | 6.62 | 6.62 | 6.62 |
| Accounts Payable | 7.1 | 18.0 | 302.0 | 487.0 | 520.0 | 617.5 | 840.0 | 1,142.8 | 1,554.7 | 2,115.0 |
| Accounts Payable, % | 14.76 | 6.56 | 1.7 | 2.53 | 7.59 | 6.63 | 6.63 | 6.63 | 6.63 | 6.63 |
| Capital Expenditure | -31.6 | -67.4 | -284.0 | -400.0 | -707.0 | -1,942.6 | -2,642.7 | -3,595.2 | -4,890.9 | -6,653.5 |
| Capital Expenditure, % | -65.69 | -24.57 | -1.6 | -2.08 | -10.32 | -20.85 | -20.85 | -20.85 | -20.85 | -20.85 |
| Tax Rate, % | -19.58 | -19.58 | -19.58 | -19.58 | -19.58 | -19.58 | -19.58 | -19.58 | -19.58 | -19.58 |
| EBITAT | -545.3 | -765.9 | 12,212.1 | 8,226.6 | -4,668.6 | -2,376.7 | -3,233.3 | -4,398.6 | -5,983.8 | -8,140.4 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -544.1 | -2,240.8 | 9,283.1 | 10,641.6 | -3,481.6 | -4,884.3 | -4,644.2 | -6,317.9 | -8,594.9 | -11,692.5 |
| WACC, % | 11.83 | 11.83 | 11.8 | 11.79 | 11.83 | 11.81 | 11.81 | 11.81 | 11.81 | 11.81 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -24,790.5 | |||||||||
| Long Term Growth Rate, % | 4.00 | |||||||||
| Free cash flow (T + 1) | -12,160 | |||||||||
| Terminal Value | -155,610 | |||||||||
| Present Terminal Value | -89,032 | |||||||||
| Enterprise Value | -113,822 | |||||||||
| Net Debt | -1,664 | |||||||||
| Equity Value | -112,158 | |||||||||
| Diluted Shares Outstanding, MM | 382 | |||||||||
| Equity Value Per Share | -293.61 |
What You Will Get
- Real Moderna Data: Preloaded financials – from revenue to EBIT – based on actual and projected figures.
- Full Customization: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- Instant Valuation Updates: Automatic recalculations to analyze the impact of changes on Moderna’s fair value.
- Versatile Excel Template: Tailored for quick edits, scenario testing, and detailed projections.
- Time-Saving and Accurate: Skip building models from scratch while maintaining precision and flexibility.
Key Features
- Real-Life MRNA Data: Pre-filled with Moderna’s historical financials and forward-looking projections.
- Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
- Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
- Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
- User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review pre-entered Moderna data (historical and projected).
- Step 3: Adjust key assumptions (yellow cells) based on your analysis.
- Step 4: View automatic recalculations for Moderna’s intrinsic value.
- Step 5: Use the outputs for investment decisions or reporting.
Why Choose This Calculator for Moderna, Inc. (MRNA)?
- Accurate Data: Access to real Moderna financials ensures dependable valuation outcomes.
- Customizable: Tailor essential parameters such as growth rates, WACC, and tax rates to align with your forecasts.
- Time-Saving: Pre-configured calculations save you the effort of starting from the ground up.
- Professional-Grade Tool: Crafted for investors, analysts, and consultants in the biotech sector.
- User-Friendly: An intuitive design and clear step-by-step guidance make it accessible for all users.
Who Should Use This Product?
- Healthcare Students: Understand vaccine development processes and analyze real-world data.
- Researchers: Integrate advanced models into studies related to biotechnology and pharmaceuticals.
- Investors: Evaluate your investment strategies and assess valuation scenarios for Moderna, Inc. (MRNA).
- Market Analysts: Enhance your analysis with a customizable DCF model tailored for biotech companies.
- Entrepreneurs: Learn from the valuation techniques used for leading biotech firms like Moderna, Inc. (MRNA).
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Moderna historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Moderna, Inc. (MRNA).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.